Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advexin + Chemo in Locally Advanced Breast Cancer
NCT00044993Phase 2Completed
- Sponsor
- Introgen Therapeutics, Inc.
- Start
- Feb 2002
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ad5CMV-p53 in breast cancer, sponsored by Introgen Therapeutics, Inc. Primary endpoint: Therapeutic efficacy. Started Feb 2002; status: completed.
02
Drugs
Ad5CMV-p53
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00044993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00044993.